Enzyvant
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2000 Centre Green Way Ste 350, Cary, Nor...Phone Number
(617) 704-9385Website
www.enzyvant.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Enzyvant
Enzyvant, a wholly owned subsidiary of Sumitovant Biopharma Ltd. (wholly owned by Sumitomo Dainippon Pharma Co., Ltd.), is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the U.S. Food and Drug Administration designation as a Regenerative Medicine Advanced Therapy (RMAT). The RVT-802 Biologics Licensing Application (BLA) was resubmitted this year and the expected action date provided by the FDA under the Prescription Drug User Fee Act (PDUFA) is October 8, 2021. The European Medicines Agency (EMA) has granted Orphan Drug designations and the Advanced Therapy Medicinal Product (ATMP) designation for RVT-802.Explore more
Enzyvant Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enzyvant your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Enzyvant
Click to see if Enzyvant had a recent Job posting/layoffs
Check out if Enzyvant is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Enzyvant recently announced quarterly report
Funding: Get notified immidiatlly once Enzyvant has new funding data
Check if Enzyvant has recently received funding, and reach out quickly before it becomes old news!
Enzyvant, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Enzyvant launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Enzyvant
Find more new buyers
Compare Similar Companies to Enzyvant
Compare insights from companies similar to Enzyvant, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Enzyvant is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Enzyvant is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Enzyvant.
Enzyvant Tech Stack
A closer look at the technologies used by Enzyvant
See more technologies
Most Recent Scoops
Left Company
Executive Move
Open Position
Open Position
Open Position
Open Position
Enzyvant News & Media
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
CAMBRIDGE, Mass., April 3, 2023 /PRNewswire/ -- Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc.,...Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
State-of-the-art facility will expand capacity for producing tissue-based and additional regenerative medicines State-of-the-art facility will expand capacity for producing tissue-based and additional regenerative medicinesEnzyvant Appoints Johanna Rossell as Chief Commercial Officer - Yahoo Finance
Industry veteran brings extensive experience including tissue-based and regenerative therapiesCAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams across several geographic markets around the world. She has delivered strong business results for companies such as NovartiSumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
LONDON and NEW YORK, Dec. 10, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant (NYSE: MYOV), a publicly listed company that is majority-owned by Sumitovant,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enzyvant
Sign Up For FreeTo access detailed company insights
Enzyvant, a wholly owned subsidiary of Sumitovant Biopharma Ltd. (wholly owned by Sumitomo Dainippon Pharma Co., Ltd.), is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, fo... Read More
